PDSB · PDS Biotechnology Corp
$0.23
0.00 (-1.11%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$12.91M
Shares
55.97M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gregory Freitag | Class A director | Appointed | 2025-06-11 |
| Stephen Glover | Class A director | Appointed | 2025-06-11 |
| Stephan F. Toutain | Chief Operations Officer | Appointed | 2024-05-02 |
| Kirk V. Shepard, M.D. | Chief Medical Officer | Appointed | 2024-01-22 |
| Lauren V. Wood, M.D. | Chief Medical Officer | Retired | 2024-01-22 |
| Lars Boesgaard | Principal Financial Officer and Principal Accounting Officer | Appointed | 2023-11-28 |
| Lars Boesgaard | Chief Financial Officer | Appointed | 2023-11-28 |
| Matthew Hill | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Resigned | 2023-11-28 |
| Ilian Iliev | Class B director | Appointed | 2023-07-17 |
| Kamil Ali-Jackson | Class B director | Appointed | 2023-07-17 |
Key facts
CIK
1472091
CUSIP
70465T107
13F (30d)
49 filings
49 filers
Visit website
Investor relations